BAX Baxter International, Inc.
Baxter International, Inc. provides portfolio of essential renal and hospital products, including acute and chronic dialysis, sterile IV solutions, infusion systems and devices, parenteral nutrition therapies; premixed and oncolytic injectable, bio surgery products and anesthetics, drug reconstitution systems; and pharmacy automation, software and services. It operates through the following segment: Americas, Europe, Middle East & Africa and Asia-Pacific. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.
Company profile
Ticker
BAX
Exchange
Website
CEO
José E. Almeida
Employees
Incorporated in
Location
Fiscal year end
Sector
Industry (SEC)
3M • Becton Dickinson & Co • ResMed • Teleflex • Hill-Rom • Boston Scientific • Integra Lifesciences • Haemonetics • NuVasive • AngioDynamics ...
SEC CIK
Corporate docs
IRS number
360781620
BAX stock data
()
Calendar
30 Jul 19
11 Dec 19
31 Dec 19
News
Company financial data Financial data
| Quarter (USD) | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|
| Revenue | 2.84B | 2.63B | 2.84B | 2.77B | |
| Net income | 343M | 347M | 348M | 544M | |
| Diluted EPS | 0.66 | 0.66 | 0.65 | 1 | |
| Net profit margin | 12.08% | 13.18% | 12.25% | 19.66% | |
| Operating income | 355M | 384M | 398M | 385M | |
| Net change in cash | 1.02B | 76M | -1.03B | 3M | |
| Cash on hand | 2.93B | 1.91B | 1.83B | 2.86B | |
| Cost of revenue | 1.68B | 1.55B | 1.65B | 1.53B |
| Annual (USD) | Dec 18 | Dec 17 | Dec 16 | Dec 15 | |
|---|---|---|---|---|---|
| Revenue | 11.13B | 10.56B | 10.16B | 9.97B | |
| Net income | 1.62B | 717M | 4.97B | 968M | |
| Diluted EPS | 2.97 | 1.29 | 9.01 | 1.76 | |
| Net profit margin | 14.60% | 6.79% | 48.85% | 9.71% | |
| Operating income | 1.6B | 1.29B | 745M | 573M | |
| Net change in cash | -1.56B | 593M | 588M | -712M | |
| Cash on hand | 1.83B | 3.39B | 2.8B | 2.21B | |
| Cost of revenue | 6.35B | 6.09B | 6.05B | 5.78B |
Financial data from company earnings reports
Financial report summary
?
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
AAKHI, absence, bundled, comparison, dedesignated, dialyzer, disease, EVO, fourth, health, Indenture, IQ, Mellon, necessitating, PrisMax, proposed, prosecution, repaid, stage, strong, Trust, Trustee, Twelfth
Removed:
adjusted, arising, core, improved, initiated, moving, nonstrategic, presenting, salary, unrecognized
Financial reports
10-Q
2019 Q2
Quarterly report
30 Jul 19
10-Q
2019 Q1
Quarterly report
8 May 19
10-K
2018 FY
Annual report
21 Feb 19
10-Q
2018 Q3
Quarterly report
5 Nov 18
10-Q
2018 Q2
Quarterly report
6 Aug 18
10-Q
2018 Q1
Quarterly report
9 May 18
10-K
2017 FY
Annual report
23 Feb 18
10-Q
2017 Q3
Quarterly report
2 Nov 17
10-Q
2017 Q2
Quarterly report
7 Aug 17
10-Q
2017 Q1
Quarterly report
4 May 17
Current reports
8-K
Baxter Receives Nyse Notice Regarding Delayed FORM10-Q Filing
22 Nov 19
8-K
Other Events
6 Nov 19
8-K
Other Events
28 Oct 19
8-K
Baxter Reports Preliminary Third Quarter 2019 Operating Results
24 Oct 19
8-K
Entry into a Material Definitive Agreement
9 Oct 19
8-K
Baxter Reports Second-quarter 2019 Results
25 Jul 19
8-K
Other Events
15 May 19
8-K
Submission of Matters to a Vote of Security Holders
10 May 19
8-K
Baxter Reports First-quarter 2019 Results
25 Apr 19
8-K
Departure of Directors or Certain Officers
21 Mar 19
Registration and prospectus
8-A12B
Registration of securities on exchange
15 May 19
424B2
Prospectus for primary offering
14 May 19
FWP
Free writing prospectus
10 May 19
424B5
Prospectus supplement for primary offering
10 May 19
S-3ASR
Automatic shelf registration
23 Aug 18
8-A12B
Registration of securities on exchange
30 May 17
424B2
Prospectus for primary offering
22 May 17
424B5
Prospectus supplement for primary offering
19 May 17
FWP
Free writing prospectus
19 May 17
424B5
Prospectus supplement for primary offering
12 Aug 16
Proxies
DEFA14A
Additional proxy soliciting materials
26 Mar 19
DEF 14A
Definitive proxy
26 Mar 19
DEF 14A
Definitive proxy
23 Mar 18
DEFA14A
Additional proxy soliciting materials
23 Mar 18
DEF 14A
Definitive proxy
17 Mar 17
DEFA14A
Additional proxy soliciting materials
17 Mar 17
DEF 14A
Definitive proxy
24 Mar 16
DEFA14A
Additional proxy soliciting materials
24 Mar 16
PRE 14A
Preliminary proxy
14 Mar 16
DEF 14A
Definitive proxy
25 Mar 15
Other
SD
Conflict minerals disclosure
24 May 19
SD
Conflict minerals disclosure
31 May 18
SD
Conflict minerals disclosure
31 May 17
CERTNYS
Certification of approval for NYSE listing
30 May 17
UPLOAD
Letter from SEC
10 May 17
CORRESP
Correspondence with SEC
28 Apr 17
CORRESP
Correspondence with SEC
14 Apr 17
UPLOAD
Letter from SEC
31 Mar 17
NO ACT
No action letter
27 Dec 16
SD
Conflict minerals disclosure
31 May 16
Ownership
SC 13D/A
Baxter International Inc
17 May 19
SC 13G
Baxter International Inc
12 Feb 19
SC 13G/A
Baxter International Inc
11 Feb 19
SC 13G/A
Baxter International Inc
4 Feb 19
SC 13D/A
Baxter International Inc
4 Dec 18
SC 13G/A
Baxter International Inc
12 Feb 18
SC 13G/A
Baxter International Inc
29 Jan 18
SC 13D/A
Baxter International Inc
2 Jun 17
SC 13D/A
Baxter International Inc
1 Mar 17
SC 13G/A
Baxter International Inc
13 Feb 17
Patents
APP
Utility
Optical Imaging System with Multiple Imaging Channel Optical Sensing
5 Dec 19
A method of calculating a volume of a drop pendant using a microprocessor.
GRANT
Utility
System for removing uremic toxins in dialysis processes
3 Dec 19
A dialysis system comprising a sorbent cartridge for fluidly communicating with at least one of a patient or a dialyzer, the sorbent cartridge including a housing having a zirconium phosphate layer followed by at least one of a urease layer, a zirconium oxide layer, or a carbon layer; a storage container in fluid communication with the sorbent cartridge; a pump in fluid communication with the sorbent cartridge and the storage container; and a control unit in operable communication with the pump to cause the pump to (i) recirculate a dialysis fluid through the sorbent cartridge for at least two recirculation cycles such that the dialysis fluid in each cycle contacts the zirconium phosphate layer first before contacting the at least one of the urease layer, zirconium oxide layer or carbon layer, and (ii) store the dialysis fluid in the storage container after the at least two recirculation cycles.
APP
Utility
Method of Cleaning Used Dialysis Fluid Using Electrodialysis and Urea Oxidation
28 Nov 19
A method of cleaning used dialysis fluid having urea to produce a cleaned dialysis fluid, the method including passing the used dialysis fluid having urea through a combination electrodialysis and urea oxidation cell, the cell including (i) a first set of electrodes for separation of the used dialysis fluid having urea into an acid stream and a basic stream, wherein the first set of electrodes includes an anode and a cathode; (ii) one or more second set of electrodes positioned to contact the basic stream with an electrocatalytic surface for decomposition of urea via electrooxidation, wherein the one or more second set of electrodes includes an anode and a cathode; and (iii) at least one power source to provide the first and second sets of electrodes with an electrical charge to activate the electrocatalytic surface.
APP
Utility
Dual Chamber Flexible Container and Drug Product Using Same
21 Nov 19
A multiple chamber container includes a first sheet; a second sheet; a first peel seal between the first and second sheets, the first peel seal extending across the first and second sheets; wherein at a first time at least one strong seal is provided around a periphery of the first and second sheets so as to leave an opening between the first and second sheets, and wherein a second peel seal is provided between the first and second sheets, the second peel seal extending across the opening between the first and second sheets; and wherein at a second time the second peel seal is removed and the at least one strong seal is extended to seal the opening between the first and second sheets.
APP
Utility
Method of Making Dual Chamber Flexible Container
21 Nov 19
A multiple chamber container forming and filling method includes (i) forming at least one strong seal around a periphery of first and second sheets so as to leave an opening between the first and second sheets; (ii) forming a temporary peel seal across the opening; (iii) forming a mixing peel seal between the first and second sheets so as to separate a diluent chamber from a powdered drug chamber; (iv) adding diluent to the diluent chamber; (v) sterilizing the multiple chamber container including the diluent; (vi) opening the temporary peel seal in an aseptic environment; (vii) adding powdered drug to the powdered drug chamber through the opening; and (viii) strong sealing the opening so as to be closed.